Tel: 1-631-626-9181 (USA)   44-208-144-6005 (Europe)


Our promise to you:
Guaranteed product quality, expert customer support.


CoV-S Pseudotyped Lentivirus - Efficient Tool for Anti-CoV Antibody Screening

Coronaviruses (CoV) are a group of viruses, such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or 2019-nCoV), that cause respiratory tract infections in human.

Coronaviruses have four major structural proteins: spike, envelope, membrane, and nucleocapsid. The entry of the CoV into cells is initiated by binding of its spike envelope glycoprotein (S) to its complement host cell receptor. The SARS coronavirus (SARS-CoV or SARS-CoV-1), for example, infects human cells by attaching to the angiotensin-converting enzyme 2 (ACE2) receptor.

The life cycle of SARS-CoV-1. Figure 1. The life cycle of SARS-CoV-1.

Considering the recent outbreaks of coronavirus disease 2019 (COVID-19) caused by the newly emerged SARS-CoV-2, and the potential of future recurrence of SARS-CoV-1, development of effective and safe vaccines remains a high priority. Since CoV uses its spike glycoprotein (S) to bind its receptor and mediate virus entry, the S protein is a main target for antibody screening. CoV S glycoprotein pseudotyped virus is a useful tool for promoting the development of antibody screening. The S pseudotyped virus lacks infectivity and can be handled in BSL-2 facilities.

Creative Biogene offers CoV-S pseudotyped lentivirus product and custom service. Pseudotyped viruses expressing CoV S protein are generated by cotransfecting HEK293T cells with three plasmids: one containing a reporter gene such as GFP, one containing CoV S envelope protein encoding sequence and one containing gag/pol.

Infection of SARS-CoV-2 S pseudotyped GFP lentivirus to HEK293T-ACE2 cells. Figure 2. Infection of SARS-CoV-2 S pseudotyped GFP lentivirus to HEK293T-ACE2 cells.

Product NameCat.No.Price
SARS-CoV-2 S Pseudotyped GFP LentivirusCoV-001Inquiry
SARS-CoV-2 S Pseudotyped Luciferase LentivirusCoV-002Inquiry


  1. Graham S, Pawel Z, Stefanie G, Adeline H, Stefan P. Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research. Antiviral Res. 2013 Dec; 100(3): 605–614.
  2. Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005 Sep 16;309(5742):1864-8.
  3. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019 Mar;17(3):181-192.
  4. Masters PS. The molecular biology of coronaviruses. Adv Virus Res. 2006; 66:193-292.
  5. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
For research use only. Not intended for any clinical use.

Quick Inquiry

Verification code